GKOS · Glaukos Corp. Q2 FY2026 earnings call record财报电话会记录

“and international commercialization, market development efforts, product approvals, the efficacy of our current and future products, competitive market position, regulatory strategies, and reimbursement for our products, financial condition, and results of operations, as well as the expected impact of general macroeconomic conditions, including foreign currency fluctuations on our business and operations.”

“As a result of our second quarter outperformance, we are raising our full year 2026 net sales guidance to $680 million-$700 million, an increase of $60 million-$65 million over our prior guidance of $620 million-$635 million.”

“glaucoma franchise, we delivered record second quarter net sales of $118.5 million on strong year-over-year growth of 64%, driven by growing contributions from iDose TR, which generated sales of approximately $74 million in the second quarter.”

“Our International Glaucoma franchise delivered record net sales of $36.6 million on year-over-year growth of 17% on a reported basis and 16% on a constant currency basis.”

“As previously discussed, we continue to expect new competitive product trialing headwinds in some of our major international markets as we progress through 2026, partially offset by growing contributions from iStent infinite following its EU MDR certification and associated European commercial launches late last year.”

“Finally, our Corneal Health franchise delivered net sales of $30.4 million on year-over-year growth of 48%, including Epioxa net sales of approximately $11 million.”

“First on international glaucoma, I would say we've increased our expectations there now where we expect to achieve low to mid-teens year-over-year growth for the overall year.”

“We'll continue to navigate competitive dynamics in those international markets and some reimbursement headwinds that have emerged in Germany and Switzerland.”

“There certainly are some new, but I would say it's been much more about taking a look at our prior base of customers and leaning into those folks that historically have both geographically and from a patient-focused standpoint, provided the optimum care in terms of their treatment times.”

“Again, like we've said to investors in the past, given our company's gross margin profile, there's certainly a clear line of sight that we have today towards Glaukos seeing profitability at some point in the future.”

“Maybe even more importantly or equally as important, we saw a nice uptick in activity around the commercial and Medicare Advantage patient populations, as well as more of our customers started to expand utilization of iDose into those patient populations.”

“Now, that all said, we'll continue to stick with our targeted guidance range for the year of a gross margin of 84%-86%.”